This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZGNX Zogenix (ZGNX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Zogenix Stock (NASDAQ:ZGNX) 30 days 90 days 365 days Advanced Chart Get Zogenix alerts:Sign Up Key Stats Today's Range$26.68▼$26.6850-Day Range$26.10▼$26.6852-Week Range$11.03▼$26.90Volume94 shsAverage Volume3.76 million shsMarket Capitalization$1.50 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. Read More Receive ZGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter. Email Address ZGNX Stock News HeadlinesNeedle-Free Drug Injection Systems Business Analysis Report 2023-2030 Featuring AKRA Dermojet, Crossject, D`Antonio Consultants, PharmaJet, and ZogenixAugust 1, 2024 | globenewswire.comHwasung Industrial Co Ltd 002460March 23, 2024 | morningstar.comMGold Hit $3,500. Here’s What’s Next…Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldman Sachs and JPMorgan forecasting as high as $6,000, now may be the most critical time in a generation to move.August 22 at 2:00 AM | Reagan Gold Group (Ad)Alcon (NYSE: ALC)July 6, 2023 | fool.comLongeveron Inc Ordinary Shares - Class AMay 20, 2023 | morningstar.comMHow Women Lead #GetonBoard Week Honorees Are Helping Catapult Fearless Women Leaders into Board Seats - Business WireOctober 11, 2022 | businesswire.comBiocryst PharmaceuticalsSeptember 30, 2022 | forbes.comNippon Shinyaku : Fintepla® (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet syndrome - Marketscreener.comSeptember 26, 2022 | marketscreener.comMSee More Headlines ZGNX Stock Analysis - Frequently Asked Questions How were Zogenix's earnings last quarter? Zogenix, Inc. (NASDAQ:ZGNX) issued its earnings results on Thursday, November, 4th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.96) by $0.08. The firm's revenue for the quarter was up 690.6% on a year-over-year basis. Read the conference call transcript. What other stocks do shareholders of Zogenix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zogenix investors own include Bristol Myers Squibb (BMY), QUALCOMM (QCOM), Gilead Sciences (GILD), GW Pharmaceuticals (GWPH), Intel (INTC), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings11/04/2021Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ZGNX CIK1375151 Webwww.zogenix.com Phone(510) 550-8300Fax858-259-1166Employees218Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$209.38 million Net Margins-278.38% Pretax Margin-278.26% Return on Equity-91.20% Return on Assets-43.60% Debt Debt-to-Equity Ratio0.88 Current Ratio3.63 Quick Ratio4.74 Sales & Book Value Annual Sales$81.69 million Price / Sales18.36 Cash FlowN/A Price / Cash FlowN/A Book Value$6.64 per share Price / Book4.02Miscellaneous Outstanding Shares56,227,000Free Float53,922,000Market Cap$1.50 billion OptionableOptionable Beta0.89 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ZGNX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access